ISRCTN66955626
Completed
Not Applicable
on-interventional study on the subcutaneous application of gammanorm®
Octapharma GmbH (Germany)0 sites100 target enrollmentSeptember 23, 2014
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Primary immunodeficiency syndromes/severe secondary hypogammaglobulinaemia
- Sponsor
- Octapharma GmbH (Germany)
- Enrollment
- 100
- Status
- Completed
- Last Updated
- 11 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients of any gender and age, who receive treatment with gammanorm®
Exclusion Criteria
- •Hypersensitivity to any of the components
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 1
Clinical study with subsequent subcutaneous administration of GEN0101 in the patients enrolled in the Phase 1 dose-escalation, safety / tolerability and preliminary efficacy study of intratumoral and subcutaneous administration of GEN0101 (GEN0101-JM003).JPRN-UMIN000026892Osaka University Hospital, Center for respiratory6
Completed
Not Applicable
Evaluation of the effect of Carrogated drain in reducing SSICondition 1: Acute abdomen. Condition 2: Acut peritonitis. Condition 3: Biliary peritonitis. Condition 4: Fecal peritonitis.Acute abdomenPeritonitisR10.0IRCT20201022049115N1Tehran University of Medical Sciences158
Recruiting
Phase 2
A Study of Ketamine in Elderly Patients with Depression.ACTRN12617001130358niversity of Otago24
Unknown
Phase 3
An open-label study of subcutaneous injection (s.c.) S-811717 (oxycodone hydrochloride solution for injection) in patients with cancer paiJPRN-jRCT2080220763SHIONOGI & CO., LTD.
Active, not recruiting
Phase 1
Subcutaneous verus intravenous morphine in palliative cancer patientsCancer pain not responding to oral opioids in palliative cancer patient, where switching to the parenteral route is indicated.Therapeutic area: Diseases [C] - Symptoms and general pathology [C23]EUCTR2021-003427-14-NOAkershus University Hospital60